About: Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial Goto Sponge NotDistinct Permalink

An Entity of Type : wikibase:Item, within Data Space : wikidata.demo.openlinksw.com associated with source document(s)

scientific article published on 01 June 1995

Attributes	Values
rdf:type	Item
description	wetenschappelijk artikel (nl) наукова стаття, опублікована в червні 1995 (uk) article scientifique publié en 1995 (fr) im Juni 1995 veröffentlichter wissenschaftlicher Artikel (de) artículu científicu espublizáu en xunu de 1995 (ast) scientific article published on 01 June 1995 (en)
publication date	wds:Q72240695-5FB9CB16-24D0-4DDA-9632-86CC6649975C
publication date	1995-06-01 00:00:00Z (xsd:dateTime)
language of work or name	wds:Q72240695-E621E785-C8F9-4094-9D29-73D92139D30F
language of work or name	English
author name string	wds:Q72240695-42B43FED-856D-41C4-8501-1BAC572BBA1A wds:Q72240695-8BBF335A-19BE-46D1-9349-209AA01A6D24 wds:Q72240695-CC518B26-8A24-449A-A5F2-34C84BD74977 wds:Q72240695-CD07CFED-390E-481F-86C2-C1FFE01E55DF wds:Q72240695-DAC45451-CE39-4645-B671-221069D3EB32
author name string	W F Whitmore H W Herr P C Sogani W R Fair D M Schwalb
rdfs:label	Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial (en) Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial (nl)
skos:prefLabel	Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial (en) Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial (nl)
name	Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial (en) Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial (nl)
author	wds:Q72240695-A335A849-E8A7-4F89-84E7-13EE1EB2EF4D wds:Q72240695-E303240B-7EAA-4B1B-A349-7DAFE8C85B08
author	Zuo-Feng Zhang Herbert F. Oettgen
title	wds:Q72240695-E1C1187B-C8BB-42DF-A533-4207A953CD6F
title	Intravesical bacillus Calmette-Guérin therapy prevents tumor progression and death from superficial bladder cancer: ten-year follow-up of a prospective randomized trial (en)
page(s)	wds:Q72240695-993EEC20-113E-415A-9167-A2C6540E3AF9
page(s)	1404-1408
instance of	wds:Q72240695-F89862D7-E6C0-4A4D-A361-588B902B1671
instance of	scholarly article
uses	wds:Q72240695-454B6448-8231-4EB6-89F1-368C0029F1F9
uses	randomized experiment
main subject	wds:Q72240695-BC4D50AA-46CD-49B5-B6A3-FC5608AF916B wds:Q72240695-C1C4D99C-2742-4F69-9960-6C7D181AF7DB
main subject	bladder cancer tumor progression
PubMed ID	wds:Q72240695-B1F821AD-8418-4D33-B652-B73643CC6ED9
PubMed ID	http://rdf.ncbi.nlm.nih.gov/pubchem/reference/7751885
PubMed ID	7751885
published in	wds:Q72240695-082239D9-0E54-4ADF-B6D7-2E00425E3EB4
published in	Journal of Clinical Oncology
issue	wds:Q72240695-ECC07CC0-6A35-47D8-9BBF-92D8BAB6F975
volume	wds:Q72240695-A430C6B0-0ABE-4AC0-846F-0630CFFDC313
issue	6
volume	13
DOI	wds:Q72240695-60CE12E6-5C0E-4EDE-A0C8-5490CCB31057
DOI	http://dx.doi.org/10.1200/JCO.1995.13.6.1404
DOI	10.1200/JCO.1995.13.6.1404
is about of	https://www.wikidata.org/wiki/Special:EntityData/Q72240695
is cites work of	Long-term follow-up of G3T1 transitional cell carcinoma of the bladder treated with intravesical bacille Calmette-Guérin: 18-year experience Androgen Dependent Regulation of bacillus Calmette-Guerin Induced Interleukin-6 Expression in Human Transitional Carcinoma Cell Lines Evaluation and follow-up strategies for superficial bladder cancer. Comparable effect with minimal morbidity of low-dose Tokyo 172 strain compared with regular dose Connaught strain as an intravesical bacillus Calmette-Guérin prophylaxis in nonmuscle invasive bladder cancer: Results of a randomized prospective compa The pharmacokinetics of Toll-like receptor agonists and the impact on the immune system. Toll-like receptors in urothelial cells--targets for cancer immunotherapy Bacillus Calmette-Guerin immunotherapy for urothelial carcinoma of the bladder 1 alpha, 25-dihydroxylvitamin D3 promotes Bacillus Calmette-Guérin immunotherapy of bladder cancer The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancer. Cytokines in cancer pathogenesis and cancer therapy Intravesical Bacillus Calmette-Guérin versus mitomycin C for Ta and T1 bladder cancer Intravesical Bacillus Calmette-Guerin in Ta and T1 Bladder Cancer Natural history of superficial bladder tumors: 10- to 20-year follow-up of treated patients Enhancement of tumour response to photodynamic therapy by adjuvant mycobacterium cell-wall treatment Chemoprevention of superficial bladder cancer Should we screen for bladder cancer in a high-risk population?: A cost per life-year saved analysis GM-CSF gene-transduced tumor vaccines Have lessons from past failures brought us closer to the success of immunotherapy in metastatic pancreatic cancer? Molecular cancer prevention: Current status and future directions Novel theranostic nanoporphyrins for photodynamic diagnosis and trimodal therapy for bladder cancer Antimicrobial peptides of the Cecropin-family show potent antitumor activity against bladder cancer cells Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa Use of licensed vaccines for active immunization of the immunocompromised host Identification of a bladder cancer-specific ligand using a combinatorial chemistry approach Nanotechnology in bladder cancer: current state of development and clinical practice Attenuated Listeria monocytogenes: a powerful and versatile vector for the future of tumor immunotherapy. Bladder cancer Bacillus Calmette-Guerin and bladder cancer IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle invasive bladder cancer Bladder cancer: race differences in extent of disease at diagnosis Localized bladder cancer The management of superficial transitional cell carcinoma of the bladder. Cost-effectiveness analysis of immediate radical cystectomy versus intravesical Bacillus Calmette-Guerin therapy for high-risk, high-grade (T1G3) bladder cancer Intravesical instillation of bacille Calmette-Guérin for superficial bladder cancer: cost-effectiveness analysis Tumor size and T stage correlate independently with recurrence and progression in high-risk non-muscle-invasive bladder cancer patients treated with adjuvant BCG. A randomized controlled trial of celecoxib to prevent recurrence of nonmuscle-invasive bladder cancer Reactive arthritis following BCG immunotherapy for urinary bladder carcinoma: a systematic review Bladder cancer: a review of diagnosis and management Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity Whole Tumor Antigen Vaccines: Where Are We? Interleukin-12. Opportunities for the treatment of bladder cancer. Combination approaches to potentiate immune response after photodynamic therapy for cancer Optimal management of high-risk T1G3 bladder cancer: a decision analysis

Faceted Search & Find service v1.16.117 as of May 05 2024

Alternative Linked Data Documents: ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3239 as of May 5 2024, on Linux (x86_64-centos_6-linux-gnu), Single-Server Edition (378 GB total memory, 172 GB memory in use)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software